Cosmos Health reports ‘no impact’ from Iran, MiddleEast conflict

Cosmos Health (COSM) confirmed that the ongoing conflict in Iran and broader Middle East geopolitical tensions have not had a material impact on the Company’s operations, supply chain, or business performance. The company also noted continued record revenue momentum and reaffirmed that its U.S. expansion, including the rollout of NOOR collagen, remains on track. Greg Siokas, CEO of Cosmos Health, stated: “Our business has never been stronger. Q3 2025 marked our highest revenue, gross profit, and gross margin in the Company’s history – and that momentum has continued. Our geographically diversified platform insulates us from regional disruptions, while the accelerating U.S. expansion of Sky Premium Life NOOR represents a transformational growth opportunity. We expect NOOR U.S. revenues to exceed $12 million within the next 12 months, at gross margins of approximately 75%, and we look forward to providing the full picture with our forthcoming 10-K filing.”